HighTower Advisors’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

HighTower Advisors’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-57,900	Closed	-$6K	–	2104
2016 Q3	$6K	Hold	57,900	–	–	﹤0.01%	1863
2016 Q2	$22K	Buy	57,900 +600	+1%	+$228	﹤0.01%	1682
2016 Q1	$22K	Buy	57,300 +1,850	+3%	+$762	﹤0.01%	2005
2015 Q4	$22K	Hold	55,450	–	–	﹤0.01%	1942
2015 Q3	$32K	Hold	55,450	–	–	﹤0.01%	1793
2015 Q2	$30K	Buy	55,450 +20,000	+56%	+$16.3K	﹤0.01%	1459
2015 Q1	$29K	Hold	35,450	–	–	﹤0.01%	1565
2014 Q4	$28K	Buy	+35,450	New	+$32.4K	﹤0.01%	1541

Other funds holding PVCT

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

HighTower Advisors's PVCT Position: Q4 2016 in Review

HighTower Advisors sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2016, closing a stake of 57,900 shares — an estimated $6K sold.

HighTower Advisors first reported a position in PVCT in Q4 2014 and held it in 8 quarters. The position peaked at $32K in Q3 2015. 8 funds tracked by Wall St. Rank hold PVCT as of Q4 2016.

HighTower Advisors reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2016 after selling out during the quarter.
HighTower Advisors sold 57,900 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2016, an estimated $6K.
HighTower Advisors first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q4 2014 and held it in 8 quarters.
HighTower Advisors's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $32K in Q3 2015.
8 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2016.

Based on HighTower Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.